Data layers Raw facts Calculated Model prediction AI interpretation

IPO Timeline Raw facts

Broker Results (T-2)
Some brokers release in afternoon
Grey Market (T-1)
Afternoon
HKEX Allotment (T-1)
Evening
Registrar Allotment (T-1)
Evening
Listing Day (T)
First day of trading

Company Overview

Stock NameHightide-B
Stock Code02511
Company Full NameTo be extracted
Industry醫療保健
Principal Activities公司為一間生物制藥公司,專注于就代謝及消化系統疾病的治療發現、開發及商業化多功能及多靶點療法。
Listing Date2023-12-22
Listing Rules EraOld Rules
Listing Rules ChapterTo be extracted
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)中國廣東省深圳市龍崗區吉華街道甘李二路中海信創新產業城18B-102
Business Address (Hong Kong)To be extracted
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitehttps://www.hightidetx.com/
Share Registrar香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited)
Registrar Contact(852)2862 8628
A-Share/US Dual ListingNo data

Offering Information

Offering Mechanism To be extracted
Offer PriceHK$ 11.50 / shares
Offer Price RangeTo be extracted
Lot SizeTo be extracted
Entry ThresholdTo be extracted
Par ValueTo be extracted
Offer PeriodTo be extracted
Global Offering SharesTo be extracted
HK Public Offer Shares (Initial)To be extracted
Public Offer Lots (Initial)To be extracted
International Placing Shares (Initial)To be extracted
Offer RatioTo be extracted
Total Shares Post-IPOTo be extracted
Greenshoe (Over-allotment Option)To be confirmed
Stabilizing Manager (Greenshoe)—
Cornerstone Share39.2%
Clawback TiersTo be extracted
Reallocation OptionTo be confirmed
Total Global Offering SizeHK$ 83,472,750

Subscription Tiers

Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.

Pool A
Lots SubscribedShares SubscribedSubscription Amount (HKD)
1 lots 500 HK$ 0
2 lots 1,000 HK$ 0
3 lots 1,500 HK$ 0
4 lots 2,000 HK$ 0
5 lots 2,500 HK$ 0
6 lots 3,000 HK$ 0
7 lots 3,500 HK$ 0
8 lots 4,000 HK$ 0
9 lots 4,500 HK$ 0
10 lots 5,000 HK$ 0
12 lots 6,000 HK$ 0
14 lots 7,000 HK$ 0
16 lots 8,000 HK$ 0
18 lots 9,000 HK$ 0
20 lots 10,000 HK$ 0
30 lots 15,000 HK$ 0
40 lots 20,000 HK$ 0
50 lots 25,000 HK$ 0
60 lots 30,000 HK$ 0
70 lots 35,000 HK$ 0
80 lots 40,000 HK$ 0
90 lots 45,000 HK$ 0
100 lots 50,000 HK$ 0
120 lots 60,000 HK$ 0
140 lots 70,000 HK$ 0
160 lots 80,000 HK$ 0
180 lots 90,000 HK$ 0
200 lots 100,000 HK$ 0
300 lots 150,000 HK$ 0
400 lots 200,000 HK$ 0
500 lots 250,000 HK$ 0
600 lots 300,000 HK$ 0
700 lots 350,000 HK$ 0
800 lots 400,000 HK$ 0
900 lots 450,000 HK$ 0
1,000 lots 500,000 HK$ 0
1,200 lots 600,000 HK$ 0
1,400 lots 700,000 HK$ 0
1,600 lots 800,000 HK$ 0
1,800 lots 900,000 HK$ 0
2,000 lots 1,000,000 HK$ 0
2,200 lots 1,100,000 HK$ 0
2,419 lots 1,209,500 HK$ 0

Stock Connect Inclusion Analysis

26Q4 Regular Review
Inclusion Pathway None
Avg Daily HK Mkt Cap ---
Est. Threshold ---
Analysis Result 无法确定入通路径

Valuation & Financials

Market Cap (at Offer Price)To be extracted
Pre-IPO Valuation (Last Round)Not disclosed
P/E RatioNot disclosed
Profit/Loss StatusTo be extracted
Period-End Cash BalanceTo be extracted
Listing ExpensesTo be extracted
Listing Expenses / Funds RaisedTo be extracted
Total Pre-IPO InvestmentTo be extracted
First Day CloseHK$ 12.38
First Day OpenHK$ 11.92
First Day Change7.65%
First Day Volume5106500.0
First Day Turnover61579300.0
Use of Proceeds
1、約155.2百萬港元(相當于所得款項凈額的80%)將用于為核心產品HTD1801的持續臨床研發活動提供資金; 2、約9.7百萬港元(相當于所得款項凈額的5%)將用于為肥胖癥的HTD1804的持續研發提供資金; 3、約19.5百萬港元(相當于所得款項凈額的10%)將用于透過持續升級及加強FUSIONTXTM開發方式進行其他候選藥物的早期藥物發現及開發; 4、約9.7百萬港元(相當于所得款項凈額的5%)將用作營運資金及其他一般企業用途。

Underwriting Syndicate

Joint Sponsors (2)
UBS Securities Hong Kong Limited CE BIN466 HUATAI FINANCIAL HOLDINGS (HONG KONG) LIMITED CE AOK809
Overall Coordinators (7)
UBS Securities Hong Kong Limited CE BIN466 HUATAI FINANCIAL HOLDINGS (HONG KONG) LIMITED CE AOK809 CLSA LIMITED CE AAB893 招银国际融资有限公司 CE AVM940 交银国际证券有限公司 CE APJ121 YUE XIU SECURITIES COMPANY LIMITED CE ABQ722 建银国际金融有限公司 CE AJO225
Joint Bookrunners (13)
UBS Securities Hong Kong Limited CE BIN466 HUATAI FINANCIAL HOLDINGS (HONG KONG) LIMITED CE AOK809 CLSA LIMITED CE AAB893 招银国际融资有限公司 CE AVM940 交银国际证券有限公司 CE APJ121 YUE XIU SECURITIES COMPANY LIMITED CE ABQ722 建银国际金融有限公司 CE AJO225 Fosun International Securities Limited CE AAF432 GOLDLINK SECURITIES LIMITED CE BHH779 I WIN SECURITIES LIMITED CE BJB315 SHENWAN HONGYUAN SECURITIES (H.K.) LIMITED CE AAC927 uSmart Securities Limited CE BJA907 WINBULL SECURITIES INTERNATIONAL (HONG KONG) LIMITED CE BRG131
Joint Lead Managers (13)
UBS Securities Hong Kong Limited CE BIN466 HUATAI FINANCIAL HOLDINGS (HONG KONG) LIMITED CE AOK809 CLSA LIMITED CE AAB893 招银国际融资有限公司 CE AVM940 交银国际证券有限公司 CE APJ121 YUE XIU SECURITIES COMPANY LIMITED CE ABQ722 建银国际金融有限公司 CE AJO225 Fosun International Securities Limited CE AAF432 GOLDLINK SECURITIES LIMITED CE BHH779 I WIN SECURITIES LIMITED CE BJB315 SHENWAN HONGYUAN SECURITIES (H.K.) LIMITED CE AAC927 uSmart Securities Limited CE BJA907 WINBULL SECURITIES INTERNATIONAL (HONG KONG) LIMITED CE BRG131

Cornerstone Investors

#Investor NameInvestment AmountShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 沧州创融股权投资基金有限公司 109,106,250 HKD — 39.21% — 6 months 2024-06-22

Directors & Management

PositionChinese nameEnglish Name
Chairman劉利平—
Company Secretary高麗萍;朱璧敏—
No director data available.

Major Shareholders

Major Shareholders & Holdings深圳市海普瑞藥業集團股份有限公司(23.61%);GREAT Mantra Group Limited(16.21%);百億投資有限公司(5.33%)
AI AI Analysis AI interpretation deepseek-v4-pro · AI-generated
!
The following content is generated by an AI model based on historical IPO data. It does NOT constitute investment advice, solicitation, or recommendation. Past subscription patterns and post-listing performance do not guarantee future results. Data may contain inaccuracies — always verify against official HKEX filings and prospectuses before making any investment decision.

Market Sentiment

The IPO of 君圣泰医药-B (02511) achieved a 32.22x oversubscription, indicating moderate retail demand but falling short of market frenzy levels. With a hit rate of 44.15%, over half of applicants walked away empty-handed, and the final offer price data is missing, limiting pricing commentary. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)

Tier Analysis

Both A-tail and B-head applicants were allocated just 1 lot each, despite applying for 800 and 900 lots respectively—a mere 0.125% allocation, erasing the typical efficiency edge of B-head. This anomaly makes the B-head application cost-inefficient due to higher margin costs without any gain in shares. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)

Demographics

No demographic breakdown (Mainland/HK ratios, regional data) is available for this listing, possibly due to reporting gaps for pharmaceutical B-shares, limiting analysis of investor composition. Without this data, common trends like Guangdong dominance or mainland participation cannot be confirmed. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)

About this page

This page shows Hightide-B (02511) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect